BioCorRx Inc.

BioCorRx sells to a mix of clinics, distributors, and end-market patients participating in its treatment and wellness programs. The clinic-related revenue comes from licensed clinics treating patients, which suggests a B2B-to-patient service model where the clinic is the paying counterparty and the patient is the end user. The newer Lucemyra® activity is tied to distribution partners under exclusive and nonexclusive agreements, making distributors and supply-chain counterparties an increasingly important customer group. The company also serves consumers enrolled in its UnCraveRx™ weight loss management program, although management disclosed that customer counts in that program have declined. Overall, demand appears fragmented and small-scale, with revenue sensitive to clinic utilization, distributor execution, and program enrollment.

BioCorRx's near-term strategy appears centered on monetizing the Lucemyra® asset through distribution agreements while preserving its clinic and program-based revenue streams. Management highlighted several exclusive and nonexclusive distribution agreements entered into in connection with the USWM LLC Asset Purchase Agreement, indicating a shift toward product distribution and profit-share economics. At the same time, the company is still trying to sustain its legacy clinic access and UnCraveRx™ program activity, even though those lines have weakened. The filings also make clear that capital raising remains a strategic necessity, because the company cannot fund its operating plan from current cash alone. In practical terms, the strategy is about building a revenue bridge from small service revenues toward a more scalable distribution model, but execution and financing risk remain high.